Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sneha Sura"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/5f19ee6381ac40d982e82e7db0d397fe
Autor:
David Waterhouse, Laura Iadeluca, Sneha Sura, Keith Wilner, Birol Emir, Stan Krulewicz, Janet Espirito, Lauren Bartolome
Publikováno v:
Targeted Oncology
Background Crizotinib was the first oral targeted therapy approved by the US Food and Drug Administration (FDA), on 11 March 2016, for c-ros oncogene 1 (ROS1)-positive advanced non-small-cell lung cancer (NSCLC). Data to support long-term clinical be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52738acf64628ec57dfcffa772cc8015
http://europepmc.org/articles/PMC8783880
http://europepmc.org/articles/PMC8783880
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundSince the introduction of immunotherapy (I/O) in 2014, increasing number of patients with solid tumor are treated with I/O. This study aimed to describe demographic and clinical characteristics of patients initiating I/O versus non-I/O-base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d736d0817d383501017834e31b8d990
https://doaj.org/article/5f19ee6381ac40d982e82e7db0d397fe
https://doaj.org/article/5f19ee6381ac40d982e82e7db0d397fe
Autor:
Neil J. Shah, Sneha Sura, Reshma Shinde, Junxin Shi, Rodolfo F. Perini, Singhal Puneet, Nicholas J. Robert, Nicholas J. Vogelzang, Robert J. Motzer
Publikováno v:
Journal of Clinical Oncology. 40:331-331
331 Background: IO agents and TKIs have revolutionized treatment landscape of mRCC pts. Despite robust clinical trials’ data for these agents, real-world (rw) clinical outcomes data, especially from community setting in the US is limited. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7739bf669ca34366e65fc055fe885cf1
https://doi.org/10.1200/jco.2022.40.6_suppl.331
https://doi.org/10.1200/jco.2022.40.6_suppl.331
Autor:
Neil J. Shah, Sneha Sura, Reshma Shinde, Junxin Shi, Rodolfo F. Perini, Singhal Puneet, Nicholas J. Robert, Nicholas J. Vogelzang, Robert J. Motzer
Publikováno v:
Journal of Clinical Oncology. 40:302-302
302 Background: Several immune-oncology (IO) agents and/or tyrosine kinase inhibitors (TKIs) have received approval for treatment of mRCC in 1L setting by Food and Drug Administration (FDA) over last few years. Limited data exists on evolving real-wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6003cc92cf4b93f5a7021be937a163fd
https://doi.org/10.1200/jco.2022.40.6_suppl.302
https://doi.org/10.1200/jco.2022.40.6_suppl.302
Publikováno v:
Blood. 138:4980-4980
Introduction: Molecular genetic testing is essential to inform disease diagnosis, prognosis, and treatment selection for patients with acute myeloid leukemia (AML). The standard treatment is induction chemotherapy followed by post-remission consolida
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f0d9c7693ac2e2521ff343fd50a2377
https://doi.org/10.1182/blood-2021-147008
https://doi.org/10.1182/blood-2021-147008